{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:47:02Z","timestamp":1790804822393,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Postinflammatory hyperpigmentation (PIH) is a skin disorder characterized by hyperpigmentation resulting from heightened inflammation and\/or damage to the basement membrane, melanocytes, and keratinocytes, leading to abnormal and excessive pigment deposition. Oral tranexamic acid (TXA), originally used as an antifibrinolytic for managing excessive bleeding, has garnered attention for its demonstrated safety and efficacy in treating melasma. There is a growing body of evidence regarding the use of TXA in the treatment of PIH.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To review the mechanism of action of oral TXA in treating PIH and examine the use of oral TXA in preventing and\/or treating PIH associated with laser-based and light-based treatments in individuals with skin color.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>Review of relevant articles from 2000 to present found in the Cochrane Library, PubMed, Embase, and Google Scholar, regarding the use of oral TXA in the treatment of PIH.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Studies reviewed investigated the efficacy of oral tranexamic acid (TXA) in treating postinflammatory hyperpigmentation (PIH) and use in preventing PIH when used in conjunction with other treatments. All studies demonstrated significant improvement in PIH without significant adverse effects and side effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Oral tranexamic acid is emerging as a safe and effective treatment in the prevention and treatment of postinflammatory hyperpigmentation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000004400","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T15:00:09Z","timestamp":1727708409000},"page":"S219-S224","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Oral Tranexamic Acid for Prevention and Treatment of Postinflammatory Hyperpigmentation"],"prefix":"10.1097","volume":"50","author":[{"given":"Marine","family":"Minasyan","sequence":"first","affiliation":[{"name":"Western University College of Osteopathic Medicine of the Pacific, Pomona, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hogan","sequence":"additional","affiliation":[{"name":"Assistant Clinical Professor of Dermatology, The George Washington School of Medicine and Health Sciences, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Lal","sequence":"additional","affiliation":[{"name":"Pediatric and Cosmetic Dermatologist, Northwell Health, NY"},{"name":"Director of Cosmetic Dermatology, Affiliated Dermatology, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"R3-20241126","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jaad.2017.01.035","article-title":"Postinflammatory hyperpigmentation: a compre- hensive overview: epidemiology, pathogenesis, clinical pre-sensation, and noninvasive assessment technique","volume":"77","author":"Silpa-Archa","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R4-20241126","first-page":"20","article-title":"Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color","volume":"3","author":"Davis","year":"2010","journal-title":"J Clin Aesthet Dermatol"},{"key":"R5-20241126","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1600-0749.2006.00338.x","article-title":"Relationship between skin response to ultraviolet exposure and skin color type","volume":"19","author":"Del Bino","year":"2006","journal-title":"Pigment Cell Res"},{"key":"R6-20241126","first-page":"718","article-title":"Therapeutic Insights in melasma and hyperpigmentation management","volume":"18","author":"Huerth","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"R7-20241126","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40257-021-00633-4","article-title":"The pathogenesis and management of acne-induced post-inflammatory hyperpigmentation","volume":"22","author":"Elbuluk","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"R8-20241126","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jid.2021.09.031","article-title":"Transcriptome analysis reveals intrinsic proinflammatory signaling in healthy African American skin","volume":"142","author":"Klopot","year":"2022","journal-title":"J Invest Dermatol"},{"key":"R9-20241126","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.clindermatol.2019.04.010","article-title":"Aging in skin of color","volume":"37","author":"Venkatesh","year":"2019","journal-title":"Clin Dermatol"},{"key":"R10-20241126","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.2147\/CCID.S385162","article-title":"Post-inflammatory hyperpigmentation in Dark skin: Molecular mechanism and Skincare Implications","volume":"15","author":"Markiewicz","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R11-20241126","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-4632.2007.03463.x","article-title":"Acne on pigmented skin","volume":"46","author":"Poli","year":"2007","journal-title":"Int J Dermatol"},{"key":"R12-20241126","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0093-3619(09)79388-8","article-title":"Differences in acne treatment prescribing patterns of pediatricians and dermatologists: an analysis of nationally representative data","volume":"2010","author":"Thiboutot","year":"2010","journal-title":"Yearb Dermatol Dermatol Surg"},{"key":"R13-20241126","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/CCID.S158129","article-title":"The impact of acne and facial post-inflammatory hyperpigmentation on quality of life and self-esteem of newly admitted Nigerian undergraduates acne and facial post-inflammatory hyperpigmentation on quality of life and self-esteem of newly admitted Nigerian undergraduates","volume":"11","author":"Akinboro","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R15-20241126","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2165\/00003495-199957060-00017","article-title":"Tranexamic acid: a review of its use in surgery and other indications","volume":"57","author":"Dunn","year":"1999","journal-title":"Drugs"},{"key":"R16-20241126","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/ced.12835","article-title":"Efficacy and possible mechanisms of topical tranexamic acid in melasma","volume":"41","author":"Kim","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"R17-20241126","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jdermsci.2007.01.009","article-title":"The vascular characteristics of melasma","volume":"46","author":"Kim","year":"2007","journal-title":"J Dermatol Sci"},{"key":"R18-20241126","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1248\/jhs.53.389","article-title":"Mechanism of the inhibitory effect of tranexamic acid on melanogenesis in cultured human melanocytes in the presence of keratinocyte-conditioned medium","volume":"53","author":"Maeda","year":"2007","journal-title":"J Health Sci"},{"key":"R19-20241126","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.thromres.2019.05.003","article-title":"Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: a systematic review and meta-analysis","volume":"179","author":"Chornenki","year":"2019","journal-title":"Thromb Res"},{"key":"R20-20241126","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1085-5629(97)80034-X","article-title":"Post-inflammatory hypopigmentation and hyperpigmentation","volume":"16","author":"Ruiz-Maldonado","year":"1997","journal-title":"Semin Cutan Med Surg"},{"key":"R21-20241126","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0923-1811(92)90050-L","article-title":"Determination of the action spectrum for UV-induced plasminogen activator synthesis in mouse keratinocytes in vitro","volume":"4","author":"Takashima","year":"1992","journal-title":"J Dermatol Sci"},{"key":"R22-20241126","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5021\/ad.2015.27.3.250","article-title":"Tranexamic acid Diminishes laser-induced melanogenesis","volume":"27","author":"Kim","year":"2015","journal-title":"Ann Dermatol"},{"key":"R23-20241126","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1600-0749.2005.00287.x","article-title":"Sphingosylphosphorylcholine-induced ERK activation inhibits melanin synthesis in human melanocytes","volume":"19","author":"Kim","year":"2006","journal-title":"Pigment Cell Res"},{"key":"R24-20241126","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3126\/kumj.v10i4.10993","article-title":"Oral tranexamic acid for the treatment of melasma","volume":"10","author":"Karn","year":"2012","journal-title":"Kathmandu Univ Med J"},{"key":"R25-20241126","first-page":"62","article-title":"Dramatic improvement of long lasting post-inflammatory hyperpigmentation by oral and topical tranexamic acid","volume":"2","author":"Kim","year":"2012","journal-title":"J Cosmet Dermatol Sci Appl"},{"key":"R26-20241126","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/14764172.2015.1114634","article-title":"Combination treatment of low- fluence Q-switched Nd: YAG laser and oral tranexamic acid for post-inflammatory hyperpigmentation due to allergic contact dermatitis to henna hair dye","volume":"18","author":"Lee","year":"2016","journal-title":"J Cosmet Laser Ther"},{"key":"R27-20241126","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1524-4725.2011.01957.x","article-title":"A prospective randomized controlled study of oral tranexamic acid for preventing postinflammatory hyperpigmentation after Q-switched ruby laser","volume":"37","author":"Kato","year":"2011","journal-title":"Dermatol Surg"},{"key":"R28-20241126","doi-asserted-by":"crossref","first-page":"344","DOI":"10.36849\/JDD.5622","article-title":"The use of tranexamic acid to prevent and treat post-inflammatory hyperpigmentation","volume":"20","author":"Lindgren","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"R29-20241126","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/lsm.23135","article-title":"A prospective randomized controlled study of oral tranexamic acid for the prevention of postinflammatory hyperpigmentation after Q-switched 532-nm Nd: YAG laser for solar lentigines","volume":"51","author":"Rutnin","year":"2019","journal-title":"Lasers Surg Med"},{"key":"R31-20241126","first-page":"387","article-title":"Common dermatologic disorders in skin of color: a comparative practice survey","volume":"80","author":"Alexis","year":"2007","journal-title":"Cutis"},{"key":"R32-20241126","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1365-4362.2003.01358.x","article-title":"Study of the skin disease spectrum occurring in an Afro-Caribbean population","volume":"42","author":"Dunwell","year":"2003","journal-title":"Int J Dermatol"},{"key":"R33-20241126","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1684\/ejd.2018.3494","article-title":"Analysis of the effect of different doses of oral tranexamic acid on melasma: a multicentre prospective study","volume":"29","author":"Zhu","year":"2019","journal-title":"Eur J Dermatol"},{"key":"R34-20241126","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jdin.2024.03.006","article-title":"Oral tranexamic acid treatment beyond 6 months for melasma patients - a retrospective case series","volume":"15","author":"Lam","year":"2024","journal-title":"JAAD Int"},{"key":"R35-20241126","doi-asserted-by":"crossref","first-page":"100882","DOI":"10.1016\/j.eclinm.2021.100882","article-title":"Oral tranexamic acid and thrombosis risk in women","volume":"35","author":"Meaidi","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R36-20241126","doi-asserted-by":"crossref","first-page":"189","DOI":"10.25259\/IJDVL_530_2021","article-title":"The optimal dose of oral tranexamic acid in Melasma: a network meta-analysis","volume":"89","author":"Wang","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R37-20241126","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s00266-012-9899-9","article-title":"Treatment of melasma with oral administration of tranexamic acid","volume":"36","author":"Wu","year":"2012","journal-title":"Aesthet Plast Surg"},{"key":"R39-20241126","doi-asserted-by":"crossref","first-page":"41","DOI":"10.25259\/IJDVL_1157_2022","article-title":"Prescribing practices of tranexamic acid for melasma: Delphi consensus from the pigmentary disorders Society","volume":"90","author":"Sarkar","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R40-20241126","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/DSS.0000000000003122","article-title":"Real-world experience with oral tranexamic acid and lasers for pigmentary disorders: a 5-year safety review","volume":"47","author":"Wang","year":"2021","journal-title":"Dermatol Surg"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T17:04:45Z","timestamp":1732640685000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":35,"journal-issue":{"issue":"12S","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000004400","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]}}}